⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 15, 2025Open Access

Figure 1 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit

Camila Bragança Xavier Clark R. Andersen JoAnn Lim Julian H. Slade Stacie A. Bean Lei Kang Hung Le Apostolia M. Tsimberidou Aung Naing David S. Hong Ecaterina E. Dumbrava Jordi Rodón Paula R. Pohlmann Sarina A. Piha‐Paul Stéphane Champiat Timothy A. Yap Tin‐Yun Tang Funda Meric‐Bernstam Siqing Fu

View Full Paper

Ask AI

Bookmark

Share

Key Points

Antihistamine use may influence treatment outcomes in patients with solid tumors undergoing immunotherapy trials.
The analysis highlights a potential association between antihistamine use and tumor responses, offering insights for improved therapies.
This phase I unit analysis leverages drug interaction methodologies to assess the impact on tumor responses in immunotherapy.
Understanding these interactions may enhance treatment strategies, particularly in solid tumor immunotherapy contexts.

Implication

Phase I unit analysis reveals associations between antihistamine use and tumor responses, suggesting potential treatment outcomes.

Abstract

Associations between antihistamine use and tumor responses. ABS, antibodies; AH, antihistamines; VAC, vaccines.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xavier et al. (2025) studied this question.

synapsesocial.com/papers/68d4508231b076d99fa58485 https://doi.org/10.1158/2767-9764.30126795

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Data from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit2025
2Table 2 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit2025
3Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase 1 Unit2025 · 1 citations
4Figure 2 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit2025
5Table 3 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit2025